Inhibrx Biosciences, Inc. · NASDAQ:INBX
Inhibrx Biosciences — Investor Presentation (March 2023)
47 slides from Inhibrx Biosciences's investor presentation, March 2023
Slide 1: Innovation Driven, Outcomes Focused
Innovation Driven Outcomes Focused March 2023
Slide 2: Presentation disclaimer
Presentation disclaimer This presentation contains forward-looking statements. In some cases, you can identify The Company may not actually achieve the plans, intentions or expectations disclosed forward-looking statements by the words “will,” “expect,” “intend,” “plan,” “objective,” in its forward-
Slide 3: Why Inhibrx Should Be Front and Center on Your Radar
Why Inhibrx Should Be Front and Center on Your Radar Four Biologic Programs in the Clinic All are demonstrating clinical activity with multi-billion-dollar potential peak sales. Two potentially registration-enabling programs are underway in 1H 2023. Active Discovery Process Six programs are expected
Slide 4: Innovative Approach to Biologic Therapeutic Discovery & Development
Innovative Approach to Biologic Therapeutic Discovery & Development Settlers, Broad Success Where Not Internal Others Have Pioneers Expertise Failed + Best targets are known and + The modular nature of our + First company to optimize already explored, but what is platforms and technologies and devel
Slide 5: Our Therapeutic Candidates
Our Therapeutic Candidates Potentially registration- Preclinical Phase 1 enabling + No innovation for 30+ years and multiple recombinant AAT failures + Favorable safety and tolerability profile w/potential to achieve normal AAT levels with INBRX-101- AATD monthly dosing Our Recombinant Alpha-1-Anti-
Slide 6: Our Upcoming Therapeutic Candidates
Our Upcoming Therapeutic Candidates All potential best-in-class with differentiated profiles INBRX-101- GvHD INBRX-121 Other Programs on Our Recombinant Alpha-1- Anti-trypsin Fc-Fusion Protein Our NK cell targeted IL-2 the Horizon (AAT-Fc) + De-risked opportunity with + NKp46 targeting with + FcRN A
Slide 7: Partnerships with Industry Leaders
Partnerships with Industry Leaders PARTNER FOCUS Key financial CD47 checkpoint inhibitor highlights Option to Ex-North America rights $274M to INBRX-101 AATD Cash and cash equivalents Use of INBX sdAb platform for certain cell therapy products for up to 13 programs > 30% Internal ownership 43.6M Mer
Slide 8: Near Term Expected Clinical Milestones
Near Term Expected Clinical Milestones INBRX-109 INBRX-101 (DR5) Initial mesothelioma, Ewing INBRX-109 (AATD) Start to sarcoma, pancreatic cancer, (DR5) Potentially potentially colorectal cancer and GIST registration- registration- combination study data INBRX-101 enabling Phase 2 enabling trial Cho
Slide 9: INBRX-101
INBRX-101 Recombinant Alpha-1 Antitrypsin Fc-fusion Protein
Slide 10: INBRX-101: Alpha-1 Antitrypsin Deficiency (AATD)
INBRX-101 Alpha-1 Antitrypsin Deficiency (AATD)
Slide 11: Functional AAT Levels in Healthy Individuals vs. AATD Patients
Functional AAT Levels in Healthy Individuals vs. AATD Patients 80 Disease history + Alpha-1 antitrypsin deficiency (AATD) is an inherited orphan 60 respiratory disease characterized by deficient levels of alpha-1 Functional AAT levels (μM) antitrypsin (AAT) + This causes loss of lung function and de
Slide 12: Current Standard of Care Does Not Maintain Normal AAT Levels
Current Standard of Care Does Not Maintain Normal AAT Levels + INBRX-101, dosed every four weeks at 120 Functional AAT serum levels at steady-state (INBRX-101 vs. pdAAT) mg/kg, is predicted to maintain patients above the lower threshold of the normal range and 80 achieve an average level (Cavg) of f
Slide 13: Potential Advantages of Recombinant AAT Fc-fusion Protein
Potential Advantages of Recombinant AAT Fc-fusion Protein Potential to extend the dosing interval from weekly to monthly AAT Has demonstrated potential to maintain patients in normal functional AAT range Fc Recombinant manufacturing provides abundant supply with no pathogen risk 13
Slide 14: INBRX-101 Topline Results from Phase 1, Part 2
INBRX-101 - Topline Results from Phase 1, Part 2 PART 2 INBRX-101 topline results – Multiple ascending 3rd dose of 40, 80 or 120 mg/kg (Q3W) 100 dose escalation (MAD) 120 mg/kg Complete Functional AAT levels (μM) 80 80 mg/kg N=18 40 mg/kg 60 N=6 40 mg/kg 40 N=6 80 mg/kg* 20 N=6 120 mg/kg* 0 Baseline
Slide 15: INBRX-101 is Present in the Lung in Every Patient Sampled
INBRX-101 is Present in the Lung in Every Patient Sampled Following IV Dosing Bronchoalveolar lavage fluid (BALF) sample collection and analysis 200 + BALF samples were collected from 3 lobes of the lung for each patient in the 80 (N = 5)1 and 120 (N = 6) mg/kg MAD cohorts prior to dosing and two we
Slide 16: INBRX-101 Potential ~$3B Annual U.S. Revenue in Severe AATD
INBRX-101 has the Potential to Achieve ~$3B in Annual U.S. Revenue with Expected Rapid Uptake in Patients with Severe AATD INBRX-101 top line projected U.S. sales & key assumptions $3.0B $3B Key assumptions + “Severe (ZZ/SZ)” AATD patients (same as pdAATs today) + 7% CAGR throughout forecast period
Slide 17: INBRX-101 Potential to Shift the Treatment Paradigm in AATD
INBRX-101 has the Potential to Shift the Treatment Paradigm, Expanding Augmentation Therapy to a Broad Group of AATD Patients in the U.S. TODAY FUTURE PI*ZZ or PI*SZ PI*ZZ or PI*SZ U.S. prevalence ~100K ~100K (same as today) ~40% (driven by increased Treatment rate ~8-10% diagnosis rates) Total trea
Slide 18: INBRX-101: Graft versus Host Disease (GvHD)
INBRX-101 Graft versus Host Disease (GvHD)
Slide 19: Strong Clinical Data and Established Guidelines for AAT Therapy in Acute GVHD
Strong Clinical Data and Established Guidelines Exist for AAT Therapy in Acute GVHD Existing clinical data for Jakafi: Existing clinical data for plasma-derived AAT therapies current standard of care 2L (steroid resistant) aGVHD Two active Phase 2/3 2L (steroid resistant) acute GVHD (aGVHD) Ruxoliti
Slide 20: INBRX-101 Potential for Fast Entry into Acute GVHD, >$1bn US Market
INBRX-101 has the Potential for Fast Entry into Acute GVHD, Expanding to Prophylaxis, Achieving >$1bn in the US Market INBRX-101 acute & prophylaxis GvHD top line projected US sales & key assumptions Key assumptions: Potential advantages over pdAAT $1,300M $1,200 + TPP: Superior safety, efficacious
Slide 21: INBRX-101 GvHD Expansion Opportunities
INBRX-101 GvHD Expansion Opportunities U.S. chronic GvHD – progression beyond steroids Prophylaxis, acute, & chronic GvHD – EU / Japan US Prevalence (2022) ~16,000 6 ~$2bn >$3bn Extensive disease requiring Europe & Japan 21,000 2, 3 2030 EU & JP 8,000 2030 US Market Allogeneic Transplants therapy (5
Slide 22: INBRX-109: Tetravalent DR5 Agonist
INBRX-109 Tetravalent DR5 Agonist
Slide 23: A Next Generation DR5 Agonist with an Optimized Balance of Efficacy and Safety
A Next Generation DR5 Agonist with an Optimized Balance of Efficacy and Safety Our Engineering Goal: Design a DR5 agonist that can selectively induce enhanced apoptosis in Death Receptor 5 (DR5/TRAIL-R2) tumor cells has been a target of interest in oncology due to the differential Our Solution:
Slide 24: Preliminary Phase 1 Data in Conventional Chondrosarcoma
Preliminary Phase 1 Data in Unresectable or Metastatic Conventional Chondrosarcoma 3mo 6mo 9mo 12mo 15mo 18mo SD (-11%) SD (-1%) IDH ► SD (-17%) SD (-20%) IDH SD (-7%) SD (-13%) IDH ► PR (-60%) SD (10%) SD (-19%) IDH ► SD (-13%) SD (5%) SD (-8%) IDH ► SD (3%) SD (-23%) IDH PR (-45%) SD (-4%) SD (16%
Slide 25: INBRX-109 Phase 2 Registration-enabling Study Design in Chondrosarcoma
INBRX-109 Phase 2 Potentially Registration-enabling Study Design in Chondrosarcoma ENDPOINTS Randomization INBRX-109 Placebo Primary: Progression free Conventional chondrosarcoma, Grades Initiated survival 1, 2 and 3, unresectable or metastatic N=134* N=67 * Secondary: Overall survival, quality of l
Slide 26: Chondrosarcoma Patient Pool of ~2.5K in the U.S.
Many Patients with Local Disease Eventually Progress to Unresectable or Metastatic Chondrosarcoma, Providing an Annual Prevalent Patient Pool of ~2.5K in the U.S. Conventional chondrosarcoma patient flow Unresectable or metastatic population (opportunity at launch) Legend: Peri-operative opportunity
Slide 27: INBRX-109 Potential ~$1B Annual Revenue
Based on Current Trends and Lack of Approved Options, INBRX-109 has the Potential to Achieve ~$1B in Annual Revenue with Rapid Uptake Post Launch INBRX-109 top line projected U.S. sales in the unresectable/metastatic setting & key assumptions $1.0B $1B Key assumptions + ~375K* annual price per patie
Slide 28: INBRX-109 on the Horizon
INBRX-109 on the Horizon PART 3 POTENTIAL FUTURE OPPORTUNITIES Combination studies Solid Tumors Ongoing + IAP antagonists Pancreatic adenocarcinoma N=20 + Targeted therapies 2nd line with mFOLFIRI + Checkpoint inhibitors Ewing sarcoma with + Selective kinase inhibitors N=20 Irinotecan + Temozolomide
Slide 29: INBRX-105: PD-L1 x 4-1BB Multispecific
INBRX-105 PD-L1 x 4-1BB Multispecific
Slide 30: Localizing and Potentiating the Anti-cancer Effects of the 4-1BB Pathway
Localizing and Potentiating the Anti-cancer Effects of the 4-1BB Pathway Our Engineering Goal: Design a 4-1BB agonist with an optimized therapeutic 4-1BB (CD137/TNFRS9) is a member of the index tumor necrosis factor (TNF) receptor Our Solution: superfamily and is an attractive target for Tetrava
Slide 31: INBRX-105 is a Potential Best-in-class 4-1BB Agonist
INBRX-105 is a Potential Best-in-class 4-1BB Agonist PD-L1 x 4-1BB Bispecifics CANDIDATE FORMAT 4-1BBL BLOCKING INBRX-105 Bivalent/Bivalent No Gen-1064 Monovalent/Monovalent n/a MCLA-145 Monovalent/Monovalent Yes FS222 Bivalent/Bivalent n/a PRS-343 Bivalent/Bivalent No ND021 Monovalent/Monovalent n/
Slide 32: INBRX-105 Potential First 4-1BB Agonist with Robust Therapeutic Window
INBRX-105 has the Potential to be the First 4-1BB Agonist with a Robust Therapeutic Window Phase 1 Trial Design PART 1 PART 2 PART 3 PART 4 Complete Ongoing Complete Ongoing Single agent dose escalation Single agent dose expansion Dose escalation with Keytruda™ Dose expansion with Keytruda™ N=32 N=6
Slide 33: INBRX-106: Hexavalent OX40 Agonist
INBRX-106 Hexavalent OX40 Agonist
Slide 34: INBRX-106 is a Potential Best-in-class OX40 Agonist
INBRX-106 is a Potential Best-in-class OX40 Agonist CANDIDATES VALENCY ISOTYPE LIGAND BLOCKING STATUS INBRX-106 Hexa- IgG1 N Ph 1 (2019) Bivalent anti- INBRX-106 OX40 Hexavalent MOXR-0916 Discontinued GSK-3174998 Discontinued OX40 OX40 BMS-986178 Ph 1 (2016) INCAGN-1949 Bi- IgG1 Y Ph 1 (2016) ABBV-3
Slide 35: Phase 1 INBRX-106 Trial as a Single Agent and with Keytruda
Phase 1 INBRX-106 Trial as a Single Agent and in Combination with Keytruda® Single agent In combination PART 1 PART 2 PART 3 PART 4 INBRX-106 single-agent Complete INBRX 106 single-agent Complete Dose escalation Complete Dose expansion Ongoing dose escalation dose expansion with Keytruda with Keytru
Slide 36: Potential Market Opportunity for INBRX-106 and INBRX-105
Potential Market Opportunity for INBRX-106 and INBRX-105 PD-1/PD-L1 WW Revenue PD-1/PD-L1 WW Revenue by Indication (in $ billions) (in $ billions) $70 $63.5 NSCLC 2020 2020 Projected 2026 $60 Melanoma Renal cell $50 carcinoma Bladder cancer $40 Head & neck cancers $30 $27.1 $28.2 Gastrointestinal ad
Slide 37: Cisleukin Platform
CisleukinTM Platform A Targeted Cis-IL2 Platform
Slide 38: Targeting the Robust Anti-tumor Effects of IL-2 to Overcome Off-target Toxicity
Targeting the Robust Anti-tumor Effects of IL-2 to Overcome Off-target Toxicity IL-2 is a potent stimulator of cytotoxic cell types with natural anti-tumor activity that has shown great promise as a single agent High affinity Targeting of IL2-X via high-affinity sdAbs in multiple cancers1 allows pin
Slide 39: INBRX-121: NK Cell Targeted Cisleukin Molecule
INBRX-121 NK Cell Targeted CisleukinTM Molecule
Slide 40: An NK Cell Targeted Cisleukin Molecule
An NK Cell Targeted CisleukinTM Molecule Description/MOA + Natural Killer (NK) cells have potent cytolytic activity and are not limited Two by MHC-I presentation of tumor-associated antigens like T cells NKp46 sdAbs designed to allow natural ligand + NKp46 is an NK cell-specific marker that maintain
Slide 41: INBRX-121 is poised to bring NK cells to the forefront of immunotherapy
INBRX-121 is poised to bring NK cells to the forefront of immunotherapy Improved NK Activity Safety with durability Multiple potential paths forward INBRX-121 NK NK Single agent NK NK Activated NK cells NK NK CYTOKINES exhibit immediate NK NK NK cytotoxicity NK INBRX-121 Combination therapy ⁺ Expand
Slide 42: Expanded mouse NK cells and enhanced their cytotoxic potential
Expanded mouse NK cells and enhanced their cytotoxic potential NK cell expansion NK cell activation NK cell cytolytic activity 25 5,000 20,000 Max. fold-change (relative to vehicle) 20 4,000 15,000 Granzyme B levels 15 3,000 KLRG1 levels 10,000 10 2,000 5,000 5 1,000 0 0 0 NK cells CD8 T cells Tregs
Slide 43: Synergized with approved therapeutic antibodies
Synergized with approved therapeutic antibodies Raji tumor growth 2,000 Vehicle 1,500 INBRX-121 Tumor Volume (mm3) 1,000 Rituxan INBRX-121 synergized with Rituxan® INBRX-121 + Rituxan in a subcutaneous 500 Raji tumor model resulting in complete 0 tumor regression 0 7 14 21 28 35 42 Dosing Time (days
Slide 44: INBRX-121 safely expanded NK cells in non-human primates
INBRX-121 safely expanded NK cells in non-human primates NK cell expansion in blood after NK Expanded NK cells a single dose of INBRX-121 at 1 mg/kg: NK in a dose-dependent NK NK manner (up to 12-fold) Frequency of lymphocytes NK NK NK NK that persists for more than Pre-dose Day 10 NK 21 days and ca
Slide 45: Expanded NK cells from Lymphoma patients
Expanded NK cells from Lymphoma patients IL-2 signaling in patient NK cells Patient NK cell proliferation 60 60 % pSTAT5 positive 40 40 % Ki67 positive 20 20 0 0 INBRX-121 - + - + - + - + INBRX-121 - + - + - + - + DLBCL MCL FL Healthy DLBCL MCL FL Healthy Donor Donor NK cells from Lymphoma patients
Slide 46: Expanded the number of NK cells while enhancing their individual cytotoxic capacities
Expanded the number of NK cells while enhancing their individual cytotoxic capacities 120 100 80 %Target celldeath Anti-hCD20-hlgG1 only INBRX-121 increased NK 60 Anti-hCD20-hlgG1 + cell-mediated killing of 40 INBRX-121 Raji cells in the presence of a Rituximab sequence 20 analog (Anti-hCD20- hIgG1)
Slide 47: Contact: Inhibrx, La Jolla, CA
11025 N. Torrey Pines Rd Ste 200 La Jolla, CA 92037 www.inhibrx.com Investor Relations: Kelly Deck, CFO [email protected]